Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a finger prick replace the needle for inflammation tests?

NCT ID NCT07435285

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a simple finger-prick blood spot can measure inflammatory markers as accurately as a standard blood draw from a vein. Researchers will collect both types of samples from 50 adults before and after a planned stressor, like a vaccine, which temporarily raises inflammation. If successful, this could offer a less painful and more convenient way to monitor inflammation in research and healthcare.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If DBS works as well as standard blood draws, it could make inflammation testing easier and less invasive for patients.
What could go wrong
This is a small, early study (50 people) comparing two sampling methods, not testing a treatment. The results may not apply to all settings or conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants who are planning to receive a seasonal vaccine OR have a scheduled acute stressor

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women aged ≥18 years, who are planning to receive a seasonal vaccine OR have a scheduled acute stressor\*. Exclusion Criteria: * Any infectious symptoms (fever, cough, rhinorrhea, sore throat, diarrhea, loss of smell or taste) within the previous 7 days * Any self-reported active/recent use of cocaine, injection drugs, or amphetamines * Acute worsening of a known chronic health condition within the previous 30 days (e.g., of IBD, COPD, asthma, rheumatologic disease) * Known severe allergy or intolerance to the planned vaccine * Contraindication to the vaccine received, if applicable \*List of possible scheduled acute stressors include: * Hard exercise (incl. 10km run or longer, high-intensity interval training, or comparable endurance activity) * Social event with moderate alcohol consumption * Planned change in medication dose and/or frequency of use * Onset of menstruation (day 1) * Other pre-planned stressors expected to elicit an inflammatory response

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood sampling are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood sampling Dried blood spot Inflammation Inflammation biomarkers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Institute of the McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H4A 0B1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.